| 國立臺灣大學 |
2008 |
Gef-H1 Couples Nocodazole-Induced Microtubule Disassembly to Cell Contractility Via Rhoa
|
張元貞; 張智芬; CHANG, YUAN-CHEN; CHANG, ZEE-FEN |
| 國立臺灣大學 |
2008-05 |
GEF-H1 couples nocodazole-induced microtubule disassembly to cell contractility via RhoA.
|
Chang, YC; Nalbant, P; Birkenfeld, J; Chang, ZF; Bokoch, GM. |
| 慈濟大學 |
2007 |
GEF-H1於乳癌轉移腫瘤細胞中受PTTG1/hSecurin的調控機制
|
廖苡竹 |
| 國立臺灣大學 |
2008 |
GEF-H1調控RhoA訊息傳遞對細胞命運決定及移動力之探討
|
張元貞; Chang, Yuan-Chen |
| 國立成功大學 |
2006-10 |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Chang, Alex; Parikh, Purvish; Thongprasert, Sumitra; Tan, Eng Huat; Perng, Reury- Perng; Ganzon, Domingo; Yang, Chih-Hsin; Tsao, Chao-Jung; Watkins, Claire; Botwood, Nick; Thatcher, Nick |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Botwood N; Thatcher N.; Watkins C; Tsao C.-J; CHIH-HSIN YANG; Ganzon D; Perng R.-P; Tan E.H; Thongprasert S; Parikh P; Chang A; Chang A;Parikh P;Thongprasert S;Tan E.H;Perng R.-P;Ganzon D;Chih-Hsin Yang;Tsao C.-J;Watkins C;Botwood N;Thatcher N. |
| 亞洲大學 |
2019-11 |
Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo
|
La, Kuang-Chi;Lai, Kuang-Chi;闕甫伈;Chueh, Fu-Shin;Hs, Yung-Ting;Hsiao, Yung-Ting;Che, Zheng-Yu;Cheng, Zheng-Yu;Jin-Cherng, L;Lien, Jin-Cherng;Li, Kuo-Ching;Liu, Kuo-Ching;Peng, Shu-Fen;Peng, Shu-Fen;鍾景光 |
| 亞洲大學 |
2019-11 |
Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo.
|
KC, Lai;KC, Lai;闕甫伈;FS, Chueh;YT, Hsiao;YT, Hsiao;ZY, Cheng;ZY, Cheng;JC, Lien;JC, Lien;KC, Liu;KC, Liu;SF, Peng;SF, Peng;JG, Chung;JG, Chung |
| 中國醫藥大學 |
2010-11 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis
|
陳偉峻(Wei-Chun chen); 陳煒(Wei- Chen); 曾冠欽(Guan-Chin Teseng); 賴學洲(Hsueh-Chou Lai); 施純明(Chuen-Ming Shih); 夏德椿(Te-Chun Hsia) |
| 中國醫藥大學 |
2010-11 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
|
陳偉峻(Wei-Chun chen);陳煒(Wei- Chen);曾冠欽(Guan-Chin Teseng);賴學洲(Hsueh-Chou Lai);施純明(Chuen-Ming Shih);夏德椿(Te-Chun Hsia) |
| 高雄醫學大學 |
2007 |
GEFITINIB AS FIRST LINE THERAPY FOR ADVANCED OR METASTATIC NSCLC PATIENTS IN SOUTHERN TAIWAN
|
洪仁宇;黃明賢 |
| 高雄醫學大學 |
2007 |
GEFITINIB AS FIRST LINE THERAPY FOR ADVANCED OR METASTATIC NSCLC PATIENTS IN SOUTHERN TAIWAN
|
洪仁宇;黃明賢 |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 國立臺灣大學 |
2009 |
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma
|
楊志新; YANG, CHIH-HSIN |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
|
Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. |
| 臺大學術典藏 |
2018-09-10T18:05:30Z |
Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?
|
Chang, C.-H. and Lee, C.-H. and Wang, J.-Y.; JANN-YUAN WANG; CHIA-HAO CHANG |
| 臺大學術典藏 |
2020-08-13T05:24:06Z |
Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?
|
Chang C.-H.;Lee C.-H.;Jann-Yuan Wang; Chang C.-H.; Lee C.-H.; JANN-YUAN WANG |
| 臺大學術典藏 |
2018-09-10T18:01:48Z |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: A cohort study in Taiwan
|
Chang, C.-H. and Lee, C.-H. and Ko, J.-C. and Chang, L.-Y. and Lee, M.-C. and Wang, J.-Y. and Yu, C.-J.; Chong-Jen Yu; JANN-YUAN WANG; CHIA-HAO CHANG; JEN-CHUNG KO; LIH-YU CHANG |
| 臺大學術典藏 |
2022-06-14T03:22:08Z |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan
|
LIH-YU CHANG |
| 臺大學術典藏 |
2017 |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Yu C.-J.; Lee M.-C.; JANN-YUAN WANG; Chang L.-Y.; Ko J.-C.; Lee C.-H.; Chang C.-H. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:34:20Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.;Lee C.-H.;Jen-Chang Ko;Chang L.-Y.;Lee M.-C.;Wang J.-Y.;Yu C.-J.; CHIA-HAO CHANG; Chih-Hsin Lee; JEN-CHANG KO; LIH-YU CHANG; Ming-Chia Lee; Jann-Yuan Wang; Chong-Jen Yu |
| 臺大學術典藏 |
2021-10-04T07:15:43Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:00:09Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; Ko J.-C.; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; CHONG-JEN YU |
